- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2017
- Public Summary Document (PSD) March 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2017 PBAC Meeting - Word
Pembrolizumab – March 2017
Pembrolizumab: Injection concentrate for I.V. infusion 100 mg in 4 mL, Powder for injection 50 mg; Keytruda®
Last updated
14 July 2017